Immuron Limited (IMRN) stock forecast & analysis
1.22
NasdaqCM · USD
Up: +0.04, +3.4%
1.18Down: -0.04, -3.3%
1 analysis
- Open
- 1.20
- Previous close
- 1.18
- Day range
- 1.15 – 1.24
- 52-week range
- 0.6770 – 2.39
- Volume (shares)
- 89.10K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 8.07M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 0.52
- Market cap
- 9.85M
Market Scanner’s AI analysis of Immuron Limited (IMRN), updated September 2026: Immuron's stock surge follows US distribution agreement for PROIBS, alongside strong technical indicators and revenue growth.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Immuron Limited (IMRN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Immuron's stock surge follows US distribution agreement for PROIBS, alongside strong technical indicators and revenue growth.
Recent analyses covered Immuron's exclusive US distribution agreement for its digestive-health product, PROIBS, which coincided with a significant stock price increase. The reports also detailed the company's quarterly revenue growth and positive trends in revenue and gross profit over recent fiscal years, alongside strong bullish technical indicators.
IMRN news & sentiment
News reports highlighted a significant stock price surge for Immuron following a US distribution agreement for its PROIBS product. Social media discussion was not covered in the provided notes.
IMRN technical picture
Technical indicators showed strong upward momentum, with the price trading well above both the 50-day and 200-day Simple Moving Averages. Short-term momentum remained strong, indicated by the 10-day Exponential Moving Average being below the last close. The Relative Strength Index and Money Flow Index readings signaled extreme buying pressure.
Fundamentals
Immuron Limited's revenue and gross profit have shown an increasing trend over recent fiscal years. However, the company has experienced negative profit, operating, and return on equity margins.
Factors discussed — upside
- Exclusive US distribution agreement secured for PROIBS
- Significant stock price surge reported
- Strong bullish technical trend with price above 50-day and 200-day SMAs
- High RSI and MFI indicating strong buying pressure
- Year-over-year quarterly revenue growth of 7.2%
Factors discussed — risks
- Negative profit margins (-49.8%)
- Negative operating margin TTM (-57.7%)
- Negative Return on Equity TTM (-40.2%)
- Distribution agreement
- Stock performance
- Technical indicators
- Financial performance
Summary updated .
IMRN technical indicators
Common technical indicators for IMRN, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 1.20 | Price above |
| 10-day exponential moving average | 1.32 | Price below |
| Relative strength index (14-day) | 47.14 | Neutral |
| MACD line (12/26/9) | 0.0359 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.80 – 1.80 | Price inside the bands |
Analyses
Recent IMRN.US analyses are locked — sign in to read them or generate a fresh one.
Frequently asked questions
- What is the bull case for Immuron Limited?
- The bull case for Immuron centers on the recent exclusive US distribution agreement for its PROIBS product, which has coincided with a significant stock price surge and strong bullish technical indicators. Analyses also noted year-over-year quarterly revenue growth and positive revenue and gross profit trends over recent fiscal years.
- What are the risks for Immuron Limited?
- Risks for Immuron include the company's negative profit margins, operating margin, and Return on Equity TTM, as indicated in recent analyses.
- Is Immuron Limited bullish or bearish?
- Recent AI analyses of Immuron Limited examined factors on both sides. Discussed upside: The bull case for Immuron centers on the recent exclusive US distribution agreement for its PROIBS product, which has coincided with a significant stock price surge and strong bullish technical indicators. Analyses also noted year-over-year quarterly revenue growth and positive revenue and gross profit trends over recent fiscal years. Discussed risks: Risks for Immuron include the company's negative profit margins, operating margin, and Return on Equity TTM, as indicated in recent analyses. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Immuron Limited?
- News reports highlighted a significant stock price surge for Immuron following a US distribution agreement for its PROIBS product. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Immuron Limited?
- Every analysis of Immuron Limited runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
- Bundles used
- gemini-low-v2
Run a fresh IMRN.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.
Or sign in to read every IMRN.US report already in the library